杜皮鲁玛
蕈样真菌病
医学
结节性痒疹
皮肤病科
特应性皮炎
湿疹性皮炎
免疫学
淋巴瘤
作者
Stefano Buffon,Silvia Alberti Violetti,Gianluca Avallone,Luigia Venegoni,Angelo Valerio Marzano,Luca Mastorino,Paolo Fava,Simone Ribero,Pietro Quaglino,Michela Ortoncelli,Silvia Ferrucci
摘要
Dupilumab is a monoclonal antibody targeting the interleukin-4 and -13 signalling pathway, and which is proven to be highly effective and safe in atopic dermatitis (AD). Its possible role in treating or inducing cutaneous T-cell lymphomas (CTCLs) has not yet been fully clarified, as several case reports seem to point not only at its beneficial effects but also at a possible pathogenetic role in mycosis fungoides and Sézary syndrome. We present data collected from a cohort of 995 patients with classic or prurigo nodularis-like AD who received dupilumab and were followed longitudinally for a mean period of 25.1 months after first administration to investigate a possible correlation between dupilumab and CTCL development.
科研通智能强力驱动
Strongly Powered by AbleSci AI